An Open Study of the Safety, Tolerability and Immunogenicity of the Drug Gam-COVID-Vac Vaccine Against COVID-19
An Open Study of the Safety, Tolerability and Immunogenicity of the Drug Gam-COVID-Vac a Solution for Intramuscular Injection With the Participation of Healthy Volunteers
Sponsor: Acellena Contract Drug Research and Development
Listed as NCT04436471, this PHASE1/PHASE2 trial focuses on Preventive Immunization COVID-19 and remains completed. Sponsored by Acellena Contract Drug Research and Development, it has been updated 7 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
▶ Show 2 earlier versions
-
Aug 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jun 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Acellena Contract Drug Research and Development
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
For direct contact, visit the study record on ClinicalTrials.gov .